Dr. Mathias Magoola, founder of Dei Bio Pharma, revealed that the firm secured patent rights for Ebola and Mpox vaccines while speaking at the 4th International Conference on Public Health in Africa. The meeting was organized by Africa Centers for Disease Control and Prevention in a bid to provide an African-led platform for public health leaders, researchers, and stakeholders to share knowledge, collaborate on solutions for the continent's unique health challenges, and build resilient health systems.
Dr. Magoola welcomed Africa's CDC's interest and support, and urged all African nations and health authorities to back Dei Bio Pharma's efforts to be designated as a continental CDMO.
"We urge all African nations and authorities to rally behind us and we are ready to sign a Memorandum of Understanding with Africa CDC to be designated as a continental CDMO," He pleaded.
He further suggested that Dei BioPharma is able to shorten the Africa CDC agenda of having 60 percent of the vaccines used in Africa manufactured from home by 2040.
African vaccine manufacturers have to increase production by 73 percent today, to achieve vaccine sovereignty by 2040. Dr. Magoola believe s his firm can help end Africa's dependence on foreign vaccines.
Mpox and Ebola cases and deaths have been observed in several African countries over the years, with the Democratic Republic of Congo (DRC) leading in outbreaks. Dr. Magoola's vaccines offers a ray of hope for Africa as far as managing infectious disease out breaks is concerned
